1. Scrip

Advent Gains High-Potential ART Business Through Bharat Buy

Deal Gives Exit To Other PE Groups

 
• By Vibha Ravi

With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The deal also provides an exit to two other PE funds - OrbiMed and Kotak.

Small shoes for the unborn baby in the belly of pregnant woman
Female Health, Assisted Reproduction Could Be Right Play For Advent • Source: Shutterstock

US-based private equity (PE) firm Advent International will acquire a majority stake from multiple shareholders in the privately-held, Indian biopharmaceutical company Bharat Serums and Vaccines Ltd (BSVL) for an undisclosed amount.

As Advent enters, two other PE funds OrbiMed Mauritius and Kotak India Equity, find an exit they have been seeking...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By Mandy Jackson

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.